Om Silakari

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2957068/publications.pdf

Version: 2024-02-01

92 papers	3,709 citations	236612 25 h-index	138251 58 g-index
93 all docs	93 docs citations	93 times ranked	6415 citing authors

#	Article	IF	Citations
1	Multiple machine learning, molecular docking, and ADMET screening approach for identification of selective inhibitors of CYP1B1. Journal of Biomolecular Structure and Dynamics, 2022, 40, 7975-7990.	2.0	13
2	3Dâ€QSAR and scaffold hopping based designing of benzo[d]oxâ€azolâ€2(3H)â€one and 2â€oxazolo[4,5â€b]pyridinâ€2(3H)â€one derivatives as selective aldehyde dehydrogenase 1A1 inhibitors: Synthesis and biological evaluation. Archiv Der Pharmazie, 2022, 355, .	2.1	10
3	Virtual screening of epalrestat mimicking selective ALR2 inhibitors from natural product database: auto pharmacophore, ADMET prediction and molecular dynamics approach. Journal of Biomolecular Structure and Dynamics, 2021, , 1-19.	2.0	3
4	Benzimidazole based hybrids against complex diseases: A catalogue of the SAR profile. European Journal of Pharmacology, 2021, 899, 174027.	1.7	13
5	Identification of kinase inhibitors that rule out the CYP27B1-mediated activation of vitamin D: an integrated machine learning and structure-based drug designing approach. Molecular Diversity, 2021, 25, 1617-1641.	2.1	1
6	Identification of potential genes associated with ALDH1A1 overexpression and cyclophosphamide resistance in chronic myelogenous leukemia using network analysis. Medical Oncology, 2021, 38, 123.	1.2	6
7	Molecular modeling approaches to address drug-metabolizing enzymes (DMEs) mediated chemoresistance: a review. Drug Metabolism Reviews, 2021, 53, 45-75.	1.5	11
8	Pharmacophore-based designing of putative ROS-1 targeting agents for NSCLC. Molecular Diversity, 2021, 25, 1091-1102.	2.1	6
9	Search for non-acidic ALR2 inhibitors: Evaluation of flavones as targeted agents for the management of diabetic complications. Bioorganic Chemistry, 2020, 96, 103570.	2.0	8
10	Investigating the Role of Missense SNPs on ALDH 1A1 mediated pharmacokinetic resistance to cyclophosphamide. Computers in Biology and Medicine, 2020, 125, 103979.	3.9	8
11	Addressing selectivity issues of aldose reductase 2Âinhibitors for the management of diabetic complications. Future Medicinal Chemistry, 2020, 12, 1327-1358.	1.1	18
12	Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19. Virus Research, 2020, 289, 198146.	1.1	37
13	Bio-Inspired Strategies against Diabetes and Associated Complications: A Review. Recent Patents on Drug Delivery and Formulation, 2020, 13, 273-282.	2.1	4
14	In silico guided development of imine-based inhibitors for resistance-deriving kinases. Journal of Biomolecular Structure and Dynamics, 2019, 37, 2593-2599.	2.0	16
15	Decoding the signature of molecular mechanism involved in mutation associated resistance to 1, 3-benzothiazin-4-ones (Btzs) based DprE1 inhibitors using BTZ043 as a reference drug. Molecular Simulation, 2019, 45, 1515-1523.	0.9	7
16	Drug metabolizing enzymes-associated chemo resistance and strategies to overcome it. Drug Metabolism Reviews, 2019, 51, 196-223.	1.5	33
17	hCES1 and hCES2 mediated activation of epalrestat-antioxidant mutual prodrugs: Unwinding the hydrolytic mechanism using in silico approaches. Journal of Molecular Graphics and Modelling, 2019, 91, 148-163.	1.3	9
18	Structure based designing of triazolopyrimidone-based reversible inhibitors for kinases involved in NSCLC. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1565-1571.	1.0	9

#	Article	IF	Citations
19	Pharmacophore modeling and molecular dynamics approach to identify putative DNA Gyrase B inhibitors for resistant tuberculosis. Journal of Cellular Biochemistry, 2019, 120, 3149-3159.	1.2	5
20	The Current Status of Oâ€Heterocycles: A Synthetic and Medicinal Overview. ChemMedChem, 2018, 13, 1071-1087.	1.6	66
21	Recent advances in colony stimulating factor-1 receptor/c-FMS as an emerging target for various therapeutic implications. Biomedicine and Pharmacotherapy, 2018, 103, 662-679.	2.5	63
22	Molecular dynamics guided development of indole based dual inhibitors of EGFR (T790M) and c-MET. Bioorganic Chemistry, 2018, 79, 163-170.	2.0	42
23	Success stories of natural product-based hybrid molecules for multi-factorial diseases. European Journal of Medicinal Chemistry, 2018, 151, 62-97.	2.6	65
24	Computational design of new protein kinase D 1 (PKD1) inhibitors: homology-based active site prediction, energy-optimized pharmacophore, docking and database screening. Molecular Diversity, 2018, 22, 47-56.	2.1	3
25	Design, synthesis and biological evaluation of 2-Phenyl-4H-chromen-4-one derivatives as polyfunctional compounds against Alzheimerâ€™s disease. Medicinal Chemistry Research, 2018, 27, 520-530.	1.1	15
26	Molecular dynamics and integrated pharmacophore-based identification of dual $$hbox {JAK3/PI3K}delta $$ JAK3/PI3K Î´ inhibitors. Molecular Diversity, 2018, 22, 95-112.	2.1	2
27	Pharmacophore and molecular dynamics based activity profiling of natural products for kinases involved in lung cancer. Journal of Molecular Modeling, 2018, 24, 318.	0.8	7
28	Mechanistic investigation of resistance via drug-inactivating enzymes inMycobacterium tuberculosis. Drug Metabolism Reviews, 2018, 50, 448-465.	1.5	12
29	Benzimidazole scaffold based hybrid molecules for various inflammatory targets: Synthesis and evaluation. Bioorganic Chemistry, 2018, 80, 24-35.	2.0	25
30	Indoles. , 2018, , 285-321.		12
31	Benzimidazole. , 2018, , 31-52.		10
32	Thiazolidine-2,4-Dione. , 2018, , 175-209.		6
33	Thiazine. , 2018, , 247-284.		6
34	An update on small molecule strategies targeting leishmaniasis. European Journal of Medicinal Chemistry, 2018, 157, 339-367.	2.6	46
35	Putative dual inhibitors of Janus kinase 1 and 3 (JAK1/3): Pharmacophore based hierarchical virtual screening. Computational Biology and Chemistry, 2018, 76, 109-117.	1.1	5
36	Identification of 2â€benzoxazolinone derivatives as lead against molecular targets of diabetic complications. Chemical Biology and Drug Design, 2018, 92, 1981-1987.	1.5	10

#	Article	IF	Citations
37	Molecular dynamics/quantum mechanics guided designing of natural products based prodrugs of Epalrestat. Journal of Molecular Structure, 2018, 1171, 556-563.	1.8	13
38	Identification of low micromolar dual inhibitors for aldose reductase (ALR2) and poly (ADP-ribose) polymerase (PARP-1) using structure based design approach. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2324-2330.	1.0	14
39	Novel EGFR (T790M)-cMET dual inhibitors: putative therapeutic agents for non-small-cell lung cancer. Future Medicinal Chemistry, 2017, 9, 469-483.	1.1	16
40	Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view. European Journal of Medicinal Chemistry, 2017, 134, 159-184.	2.6	420
41	Exploration of multi-target potential of chromen-4-one based compounds in Alzheimerâ€™s disease: Design, synthesis and biological evaluations. Bioorganic and Medicinal Chemistry, 2017, 25, 6273-6285.	1.4	24
42	Multiple target-centric strategy to tame inflammation. Future Medicinal Chemistry, 2017, 9, 1361-1376.	1.1	19
43	Oxindole-based SYK and JAK3 dual inhibitors for rheumatoid arthritis: designing, synthesis and biological evaluation. Future Medicinal Chemistry, 2017, 9, 1193-1211.	1.1	18
44	Pharmacophore based design of some multi-targeted compounds targeted against pathways of diabetic complications. Journal of Molecular Graphics and Modelling, 2017, 76, 412-418.	1.3	6
45	Chemotherapeutics-resistance â€œarmsâ€•race: An update on mechanisms involved in resistance limiting EGFR inhibitors in lung cancer. Life Sciences, 2017, 186, 25-32.	2.0	17
46	Structure-based design of new poly (ADP-ribose) polymerase (PARP-1) inhibitors. Molecular Diversity, 2017, 21, 655-660.	2.1	6
47	Ligand-based and e-pharmacophore modeling, 3D-QSAR and hierarchical virtual screening to identify dual inhibitors of spleen tyrosine kinase (Syk) and janus kinase 3 (JAK3). Journal of Biomolecular Structure and Dynamics, 2017, 35, 3043-3060.	2.0	8
48	Kinases inhibitors in lung cancer: From benchside to bedside. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1866, 128-140.	3.3	33
49	Active site fingerprinting and pharmacophore screening strategies for the identification of dual inhibitors of protein kinase C $$(hbox {PKC}{upbeta })$$ (PKC Î²) and poly (ADP-ribose) polymerase-1 (PARP-1). Molecular Diversity, 2016, 20, 747-761.	2.1	14
50	Identification of non-resistant ROS-1 inhibitors using structure based pharmacophore analysis. Journal of Molecular Graphics and Modelling, 2016, 70, 85-93.	1.3	17
51	Design, synthesis and biological evaluation of novel 2-phenyl-1-benzopyran-4-one derivatives as potential poly-functional anti-Alzheimer's agents. RSC Advances, 2016, 6, 108411-108422.	1.7	26
52	Pharmacophore and docking-based hierarchical virtual screening for the designing of aldose reductase inhibitors: synthesis and biological evaluation. Medicinal Chemistry Research, 2016, 25, 609-626.	1.1	15
53	Hybrids: a new paradigm to treat Alzheimerâ€™s disease. Molecular Diversity, 2016, 20, 271-297.	2.1	73
54	Interleukin-1 receptor associated kinase inhibitors: Potential therapeutic agents for inflammatory- and immune-related disorders. Cellular Signalling, 2015, 27, 1039-1055.	1.7	41

#	Article	IF	Citations
55	Aldose reductase inhibitors for diabetic complications: Receptor induced atom-based 3D-QSAR analysis, synthesis and biological evaluation. Journal of Molecular Graphics and Modelling, 2015, 59, 59-71.	1.3	11
56	Thiazolidine-2,4-dione derivatives: Programmed chemical weapons for key protein targets of various pathological conditions. Bioorganic and Medicinal Chemistry, 2015, 23, 2953-2974.	1.4	78
57	Integrated pharmacophore and dockingâ€based designing of dual inhibitors of aldose reductase (ALR2) and protein tyrosine phosphatase 1B (PTP1B) as novel therapeutics for insulinâ€resistant diabetes and its complications. Journal of Chemometrics, 2015, 29, 109-125.	0.7	6
58	2-Aminobenzimidazole conjugates of NSAIDS: novel compounds with immunomodulatory, anti-inflammatory and antioxidant actions. Medicinal Chemistry Research, 2015, 24, 1170-1179.	1.1	6
59	Benzimidazoleâ€“ibuprofen/mesalamine conjugates: Potential candidates for multifactorial diseases. European Journal of Medicinal Chemistry, 2015, 89, 671-682.	2.6	18
60	Synthesis, cytotoxic activity, and computational analysis of N10-substituted acridone analogs. Medicinal Chemistry Research, 2015, 24, 921-933.	1.1	12
61	Inhibitors of Microsomal Prostaglandin E₂ Synthaseâ€1 Enzyme as Emerging Antiâ€inflammatory Candidates. Medicinal Research Reviews, 2014, 34, 825-855.	5.0	38
62	Multifunctional compounds: Smart molecules for multifactorial diseases. European Journal of Medicinal Chemistry, 2014, 76, 31-42.	2.6	170
63	Dual inhibitors of Janus kinase 2 and 3 (JAK2/3): designing by pharmacophore- and docking-based virtual screening approach. Molecular Diversity, 2014, 18, 253-267.	2.1	32
64	Synthesis and pharmacological evaluation of polyfunctional benzimidazole-NSAID chimeric molecules combining anti-inflammatory, immunomodulatory and antioxidant activities. Archives of Pharmacal Research, 2014, 37, 1426-1436.	2.7	10
65	Purinergic receptor P2X7: A novel target for anti-inflammatory therapy. Bioorganic and Medicinal Chemistry, 2014, 22, 54-88.	1.4	86
66	Synthesis, cytotoxic study and docking based multidrug resistance modulator potential analysis of 2-(9-oxoacridin-10(9H)-yl)-N-phenyl acetamides. European Journal of Medicinal Chemistry, 2014, 80, 83-91.	2.6	27
67	Coumarin hybrids as novel therapeutic agents. Bioorganic and Medicinal Chemistry, 2014, 22, 3806-3814.	1.4	227
68	Pharmacophore and docking-based virtual screening approach for the design of new dual inhibitors of Janus kinase 1 and Janus kinase 2. SAR and QSAR in Environmental Research, 2014, 25, 617-636.	1.0	4
69	Insight into the therapeutic aspects of â€˜Zeta-Chain Associated Protein Kinase 70kDaâ€™ inhibitors: A review. Cellular Signalling, 2014, 26, 2481-2492.	1.7	21
70	Flavones: An important scaffold for medicinal chemistry. European Journal of Medicinal Chemistry, 2014, 84, 206-239.	2.6	399
71	Benzimidazoles: An Ideal Privileged Drug Scaffold for the Design of Multitargeted Anti-inflammatory Ligands. Mini-Reviews in Medicinal Chemistry, 2014, 14, 747-767.	1.1	36
72	Physiological Modulation Approaches to Improve Cancer Chemotherapy : A Review. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 713-749.	0.9	6

#	Article	IF	Citations
73	Inhibitors of switch kinase â€˜spleen tyrosine kinaseâ€™ in inflammation and immune-mediated disorders: A review. European Journal of Medicinal Chemistry, 2013, 67, 434-446.	2.6	46
74	3D-QSAR analysis of benzimidazole inhibitors of interleukin-2 inducible T cell kinase (ITK) considering receptor flexibility and water importance for molecular alignment. Medicinal Chemistry Research, 2013, 22, 5578-5587.	1.1	1
75	3D-QSAR analysis of anilinoquinoline inhibitors of colony stimulating factor-1 kinase (cFMS): implementation of field-based molecular alignment. Medicinal Chemistry Research, 2013, 22, 5167-5183.	1.1	4
76	Acetylcholinesterase inhibitors as Alzheimer therapy: From nerve toxins to neuroprotection. European Journal of Medicinal Chemistry, 2013, 70, 165-188.	2.6	274
77	Designing of new multi-targeted inhibitors of spleen tyrosine kinase (Syk) and zeta-associated protein of 70kDa (ZAP-70) using hierarchical virtual screening protocol. Journal of Molecular Graphics and Modelling, 2013, 39, 165-175.	1.3	26
78	Exploring the Biological Potential of Urea Derivatives Against mPGES-1: A Combination of Quantum Mechanics, Pharmacophore Modelling and QSAR Analyses. Medicinal Chemistry, 2013, 9, 138-151.	0.7	2
79	Receptor Guided 3D-QSAR Analysis of Thieno[2,3-b]Pyridine-5- Carbonitrile Inhibitors of Protein Kinase C Theta (PKC-θ). Combinatorial Chemistry and High Throughput Screening, 2013, 16, 731-738.	0.6	1
80	The therapeutic journey of benzimidazoles: A review. Bioorganic and Medicinal Chemistry, 2012, 20, 6208-6236.	1.4	637
81	Inhibitors of interleukin-2 inducible T-cell kinase as potential therapeutic candidates for the treatment of various inflammatory disease conditions. European Journal of Pharmaceutical Sciences, 2012, 47, 574-588.	1.9	21
82	Structural Basis of Amino Pyrimidine Derivatives for Inhibitory Activity of PKCâ€Î¸: 3Dâ€QSAR and Molecular Docking Studies. Molecular Informatics, 2012, 31, 659-668.	1.4	12
83	Exploring the Role of Water Molecules for Docking and Receptor Guided 3D-QSAR Analysis of Naphthyridine Derivatives as Spleen Tyrosine Kinase (Syk) Inhibitors. Journal of Chemical Information and Modeling, 2012, 52, 2619-2630.	2.5	13
84	A three-dimensional pharmacophore modelling of ITK inhibitors and virtual screening for novel inhibitors. SAR and QSAR in Environmental Research, 2011, 22, 171-190.	1.0	6
85	Anthranilate derivatives as TACE inhibitors: Docking based CoMFA and CoMSIA analyses. Journal of Molecular Modeling, 2011, 17, 9-19.	0.8	8
86	Strategy for generation of new TACE inhibitors: pharmacophore and counter pharmacophore modeling to remove non-selective hits. Medicinal Chemistry Research, 2011, 20, 760-768.	1.1	3
87	Tumor Necrosis Factor Alpha Converting Enzyme: An Encouraging Target for Various Inflammatory Disorders. Chemical Biology and Drug Design, 2010, 75, 415-443.	1.5	37
88	Three-dimensional quantitative structure-activity relationship (3D-QSAR) studies of various benzodiazepine analogues of Î³-secretase inhibitors. Journal of Molecular Modeling, 2009, 15, 343-348.	0.8	9
89	A Three Dimensional Pharmacophore Modeling for KDR and Tieâ€2 Receptor Tyrosine Kinase Inhibitors and Virtual Screening for New Multikinase Inhibitors. QSAR and Combinatorial Science, 2009, 28, 1130-1147.	1.5	3
90	Generation of Selective TACE Inhibitors: Ligand and Structure Based Molecular Modeling, Virtual Screening, Counter Pharmacophore Screening to Get Selective Molecules. QSAR and Combinatorial Science, 2009, 28, 1317-1333.	1.5	1

#	Article	IF	Citations
91	Threeâ€dimensional Quantitative Structureâ€“activity Relationship Modeling of Î³â€Secretase Inhibitors using Molecular Field Analysis. Chemical Biology and Drug Design, 2008, 71, 155-166.	1.5	5
92	Pharmacophore mapping of diverse classes of farnesyltransferase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1594-1600.	1.0	21